Bone Marrow DR+ Trephine biopsy (SHM) at Dr. Essa Lab

Bone Marrow DR+ Trephine biopsy (SHM) at Dr. Essa Lab

The Bone Marrow DR+ Trephine biopsy (SHM) is a highly specialized histopathological and hematological investigation performed to evaluate the structure, cellularity, and architectural integrity of the bone marrow. Unlike a simple bone marrow aspirate, which only extracts the liquid portion of the marrow, a trephine biopsy removes a small, solid cylindrical core of bone and intact marrow tissue. This procedure is essential for preserving the spatial relationships between different blood-forming cells, the bone trabeculae, and the supporting stromal tissue. The designation “DR+” signifies an advanced diagnostic reporting protocol, while “SHM” refers to Special Hematology Morphology, highlighting the comprehensive microscopic and immunohistochemical analysis applied to the specimen at Dr. Essa Lab.

The bone marrow is the primary site of hematopoiesis, where red blood cells, white blood cells, and platelets are produced. Evaluating this microenvironment is critical when peripheral blood tests, such as a complete blood count (CBC) or peripheral blood smear, yield abnormal or inconclusive results. By analyzing a solid core of tissue, hematopathologists at Dr. Essa Lab can accurately assess marrow cellularity, identify focal lesions, detect granulomas, and diagnose various hematological malignancies. The diagnostic value of a trephine biopsy is unparalleled, particularly in cases of a “dry tap,” where fibrotic or highly cellular marrow prevents the successful aspiration of fluid. This test provides definitive evidence required for staging lymphomas, diagnosing myeloproliferative neoplasms, and monitoring therapeutic responses.

Clinical Procedure: What to Expect

Patient Preparation

• Coagulation Profile: Patients must undergo a recent coagulation screen, including Prothrombin Time (PT), Activated Partial Thromboplastin Time (aPTT), and International Normalized Ratio (INR), to minimize the risk of post-procedure bleeding.
• Medication Review: Inform the physician about all current medications, especially anticoagulants (such as warfarin, heparin, or direct oral anticoagulants) and antiplatelet agents (like aspirin or clopidogrel). These may need to be temporarily discontinued under medical supervision.
• Allergy Notification: Disclose any known allergies to local anesthetics (such as lidocaine), antiseptic solutions (like iodine or chlorhexidine), or latex.
• Dietary Instructions: Fasting is generally not required for procedures performed under local anesthesia. A light meal prior to the appointment is recommended. However, if conscious sedation is planned, specific fasting guidelines must be followed.
• Clinical Documentation: Patients should bring all previous blood reports, imaging scans, clinical referral letters, and medical history files to Dr. Essa Lab on the day of the procedure.
• Post-Procedure Transport: It is highly recommended to arrange for a family member or friend to accompany you and drive you home after the biopsy.

During the Procedure

The Bone Marrow DR+ Trephine biopsy (SHM) is performed by an experienced clinical hematologist or trained specialist under strict aseptic conditions. The patient is typically positioned in a lateral decubitus (lying on the side) or prone (lying on the stomach) position to expose the posterior superior iliac spine of the hip bone, which is the safest and most common site for marrow collection. The skin over the biopsy site is thoroughly cleansed with an antiseptic solution and draped to maintain a sterile field. A local anesthetic is then injected into the skin, subcutaneous tissues, and down to the highly sensitive periosteum (the outer layer of the bone) to ensure maximum patient comfort.

Once the area is completely numb, a small skin incision is made. A specialized trephine biopsy needle is carefully inserted through the outer bone cortex into the marrow cavity. The physician uses a gentle rotating motion to obtain an intact, solid core of bone marrow tissue, typically measuring 1 to 2 centimeters in length. If a bone marrow aspirate is also required, it is usually collected just prior to the trephine biopsy using a separate syringe. The entire procedure takes approximately 20 to 30 minutes. While the local anesthetic prevents sharp pain, patients may experience a deep, temporary pressure sensation as the needle enters the bone. After the needle is withdrawn, firm pressure is applied to the site to control bleeding, followed by the application of a sterile pressure bandage.

When is a Bone Marrow DR+ Trephine biopsy (SHM) Performed?

Evaluation of Unexplained Cytopenias

Physicians request this biopsy when a patient presents with persistent, unexplained decreases in one or more blood cell lines, such as severe anemia, leukopenia, or thrombocytopenia. When peripheral blood examinations fail to identify the underlying cause, evaluating the bone marrow directly helps determine if the cytopenia is due to a production defect, such as aplastic anemia, or peripheral destruction.

Staging and Monitoring of Hematological Malignancies

This procedure is vital for patients diagnosed with lymphomas (both Hodgkin and Non-Hodgkin) and multiple myeloma. The trephine biopsy allows hematopathologists to determine whether malignant cells have infiltrated the bone marrow, which directly influences clinical staging, prognosis, and the selection of appropriate chemotherapy or radiation protocols.

Investigation of Myeloproliferative and Myelodysplastic Disorders

When clinical symptoms and blood tests suggest myeloproliferative neoplasms (such as polycythemia vera, essential thrombocythemia, or primary myelofibrosis) or myelodysplastic syndromes (MDS), a trephine biopsy is essential. It provides the necessary tissue architecture to identify dysplastic cellular changes, megakaryocyte clustering, and reticulin fiber deposition.

Diagnosis of Unexplained Splenomegaly or Lymphadenopathy

In patients presenting with significant enlargement of the spleen or lymph nodes without an obvious infectious cause, a bone marrow biopsy is performed. It helps identify systemic hematological disorders, metastatic solid tumors, or infiltrative diseases that may be primary drivers of the physical findings.

Assessment of Pyrexia of Unknown Origin and Granulomatous Diseases

When a patient suffers from prolonged, unexplained fever (pyrexia of unknown origin), a trephine biopsy can detect underlying chronic granulomatous infections, such as tuberculosis, histoplasmosis, or brucellosis. It also assists in diagnosing systemic inflammatory conditions and storage disorders that manifest in the marrow stroma.

What Does a Bone Marrow DR+ Trephine biopsy (SHM) Detect?

• Hypercellular bone marrow showing increased hematopoiesis across all cell lines.
• Hypocellular bone marrow indicating bone marrow failure or aplastic anemia.
• Myelofibrosis characterized by increased reticulin or collagen fiber deposition.
• Acute Myeloid Leukemia (AML) characterized by a high percentage of myeloblasts.
• Acute Lymphoblastic Leukemia (ALL) showing dense infiltration of lymphoblasts.
• Chronic Myeloid Leukemia (CML) phases, including chronic, accelerated, or blast crisis.
• Chronic Lymphocytic Leukemia (CLL) with nodular, interstitial, or diffuse infiltration patterns.
• Multiple Myeloma characterized by abnormal, monoclonal plasma cell proliferation.
• Hodgkin Lymphoma marrow involvement, marked by Reed-Sternberg cells or variant cells.
• Non-Hodgkin Lymphoma infiltration, including follicular, diffuse large B-cell, or T-cell subtypes.
• Myelodysplastic Syndrome (MDS) showing dysplastic changes in erythroid, myeloid, or megakaryocytic lineages.
• Essential Thrombocythemia characterized by clusters of giant, mature megakaryocytes.
• Polycythemia Vera presenting with panmyelosis (increased red, white, and platelet precursors).
• Metastatic carcinoma from solid tumors, such as breast, prostate, lung, or kidney cancers.
• Granulomatous inflammation indicative of tuberculosis, sarcoidosis, or fungal infections.
• Amyloidosis, detected through specialized stains showing amyloid deposition in vessel walls.
• Severe iron deficiency, confirmed by the complete absence of stainable iron in the marrow stores.
• Systemic mastocytosis, characterized by abnormal aggregates of mast cells.
• Hemophagocytic Lymphohistiocytosis (HLH) showing active hemophagocytosis by macrophages.
• Gaucher’s disease, identified by the presence of characteristic lipid-laden Gaucher cells.
• Pure Red Cell Aplasia (PRCA) showing a selective, near-complete absence of erythroid precursors.
• Infectious pathogens, including Leishmania donovani (kala-azar) or atypical mycobacteria.

Turnaround Time and Report Access at Dr. Essa Lab

The processing of a Bone Marrow DR+ Trephine biopsy (SHM) is a meticulous, multi-step laboratory procedure. Because the specimen contains solid bone, it must undergo a specialized decalcification process to soften the tissue before it can be thinly sectioned, mounted on glass slides, and stained. This decalcification step is critical for preserving cellular detail but requires additional time. At Dr. Essa Lab, the standard turnaround time for a trephine biopsy report is typically 5 to 7 working days. If advanced immunohistochemistry (IHC) stains or molecular testing are required to characterize abnormal cells, additional time may be necessary.

Dr. Essa Lab provides convenient digital access to diagnostic reports. Once the consultant hematopathologist signs off on the final report, patients receive an automated SMS notification. Reports can be viewed, downloaded, and printed directly from the official Dr. Essa Lab website or mobile application using the unique lab ID and password provided on the registration receipt. Physical copies of the reports can also be collected from any of the diagnostic center branches across Karachi and other major cities.

Bone Marrow DR+ Trephine biopsy (SHM) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Overall Cellularity	Age-appropriate cellularity (typically 30% to 70% in adults)	Hypercellular (leukemia, MPN) or Hypocellular (aplastic anemia)
Myeloid-to-Erythroid (M:E) Ratio	Balanced ratio, typically between 1.5:1 and 3:1	Increased (myeloid leukemia, infection) or Decreased (erythroid hyperplasia)
Megakaryocytes	Normal numbers, scattered, normal lobation	Atypical clusters, giant forms (ET), or dwarf micro-megakaryocytes (MDS)
Reticulin Fibrosis	Grade 0 to Grade 1 (minimal, delicate fibers)	Grade 2 to Grade 3 (dense, intersecting collagen fibers in myelofibrosis)
Trabecular Bone Architecture	Intact, normal thickness and structure	Osteosclerosis, osteopenia, or destruction by osteolytic lesions
Lymphoid Aggregates	Absent, or small, well-circumscribed reactive aggregates	Large, irregular, paratrabecular aggregates indicative of lymphoma
Iron Stores (Hemosiderin)	Adequate, stainable iron present in macrophages	Absent iron (iron deficiency) or ring sideroblasts (sideroblastic anemia)
Foreign / Non-Hematopoietic Cells	Absent	Clusters of metastatic epithelial cells (metastatic carcinoma)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Bone Marrow DR+ Trephine biopsy (SHM)?

• Experienced Healthcare Professionals: The procedure is conducted by highly trained clinical hematologists, ensuring safe sample collection and minimal patient discomfort.
• Expert Hematopathologists: Biopsy specimens are analyzed, interpreted, and reported by senior consultant hematopathologists with extensive diagnostic expertise.
• Advanced Histopathology Lab: Dr. Essa Lab utilizes state-of-the-art tissue processors, automated microtomes, and standardized decalcification protocols.
• Comprehensive IHC Panels: Access to a wide array of immunohistochemical markers to precisely classify leukemias, lymphomas, and metastatic tumors.
• Strict Quality Control: The laboratory adheres to rigorous internal and external quality assurance programs to ensure international diagnostic standards.
• Patient-Focused Care: Compassionate staff provide a supportive, comfortable, and sterile environment for all specialized clinical procedures.
• Convenient Digital Access: Secure online reporting allows patients and referring physicians to access results quickly via the web portal or mobile app.
• Trusted Diagnostic Network: With decades of service, Dr. Essa Lab is recognized as one of Pakistan’s most reliable and accurate diagnostic institutions.